Inventiva SA（IVA）股票分析IVAInventiva SA

Inventiva SA is a France-based company engaged in the biotechnology sector. The Company focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology. It operates in the Healthcare sector.

Inventiva SA (IVA) is a good buy right now due to its recent price increase of 26.19% over the last 5 days and a strong cash position of €166.1 million, which supports its operations and R&D. Furthermore, analysts have set price targets significantly higher than the current price of $3.71, with the highest target at $21, indicating a potential upside of over 465%. The main risk is the company's negative P/E ratio of -1.42, reflecting ongoing losses, but the narrowing of losses and improved cash flow management suggest a path toward profitability.